Molecular determinants of drug binding ad action on L-type calcium channels

Annual Review of Pharmacology and Toxicology

Volumn 37, Issue , 1997, Pages 361-396

  Hockerman, Gregory H ^a   Peterson, Blaise Z ^a   Johnson, Barry D ^a   Catterall, William A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

benzothiazepines; calcium channel blockers; dihydropyridines; phenylalkylamines; receptor sites

Indexed keywords

BENZAZEPINE DERIVATIVE; BENZOTHIAZEPINE DERIVATIVE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; DIHYDROPYRIDINE DERIVATIVE; PHENYLALKYLAMINE;

BINDING SITE; DRUG BINDING; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AMINO ACID SEQUENCE; BENZAZEPINES; BINDING SITES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DIHYDROPYRIDINES; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHENETHYLAMINES; PROTEIN BINDING;

EID: 0030989343     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (125)

1. Catterall WA. 1995. Structure and function of voltage-gated ion channels. Annu. Rev. Biochem. 65:493-531
2. 2+ channel diversity. Annu. Rev. Neurosci. 17:399-418
3. Birnbaumer L, Campbell KP, Catterall WA, Harpold MM, Hofmann F, et al. 1994. The naming of voltage-gated calcium channels. Neuron 13:505-6
4. 2+ channels in mammalian central neurons. Trends Neurosci. 18:89-98
5. Isom LL, De Jongh KS, Catterall WA. 1994. Auxiliary subunits of voltage-gated ion channels. Neuron 12:1183-94
6. Tanabe T, Takeshima H, Mikami A, Flockerzi V, Takahashi H, et al. 1987. Primary structure of the receptor for calcium channel blockers from skeletal muscle Nature 328:313-18
7. Mikami A, Imoto K, Tanabe T, Niidome T, Mori Y, et al. 1989. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature 340:230-33
8. Koch WJ, Ellinor PT, Schwartz A. 1990. cDNA cloning of a dihydropyridine-sensitive calcium channel from rat aorta. Evidence for the existence of alternatively spliced forms. J. Biol. Chem. 265:17786-91
9. Snutch TP, Tomlinson WJ, Leonard JP, Gilbert MM. 1991. Distinct calcium channels are generated by alternative splicing and are differentially expressed in the mammalian CNS. Neuron 7:45-47
10. 2, and β subunits of a novel human neuronal calcium channel subtype. Neuron 8:71-84
11. 1 subunit of a voltage-dependent calcium channel expressed in pancreatic β cells Proc. Natl. Acad. Sci. USA 89:584-88
12. Gould RJ, Murphy KM, Snyder SH. 1983. Studies on voltage-operated calcium channels using radioligands. Cold Spring Harbor Symp. Quant. Biol. 48:355-62
13. 125I]iodipine. J. Cardiovasc. Pharmacol. 6:S508-21
14. Triggle DJ. 1991. Calcium-channel drugs: structure-function relationships and selectivity of action. J. Cardiovasc. Pharmacol. 18:S1-S6
15. 3H-desmethoxyverapamil labelling of putative calcium channels in brain: autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites. Naunyn-Schmidede. Arch. Pharmacol. 327:183-87
16. 3H]nitrendipine binding by the calcium channel antagonist verapamil and diltiazem in rat brain synaptosomes. J. Pharmacol. Exp. Ther. 229:333-39
17. Diochot S, Richard S, Baldy-Moulinier M, Nargeot J, Valmier J. 1995. Dihydropyridines, phenylalkylamines and benzothiazepines block N-, P/Q- and R-type calcium currents. Pflugers Arch. 431:10-19
18. Galper J, Catterall WA. 1979. Inhibition of sodium channels by D600. Mol. Pharmacol. 15:174-78
19. + channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol. 40:756-65
20. + channel cloned from human heart. Mol Pharmacol. 44:1240-45
21. + channels Kv1.2 and Kv1.4. Eur. J. Pharmacol. 281:151-59
22. Lee KS, Tsien RW. 1983. Mechanism of calcium channel blockade by verapamil, D600, diltiazem, and nitrendipine in single dialysed heart cells. Nature 302:790-94
23. Sanguinetti MC, Kass RS. 1984. Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. Circ. Res. 55:336-48
24. Uehara A, Hume JR. 1985. Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. J. Gen. Physiol. 85:621-47
25. Hille B. 1977. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J. Gen. Physiol. 69:497-515
26. Hondeghem LM, Katzung BG. 1984. Antiarrythmic agents: the modulated receptor mechanism of action of sodium and calcium channel blocking drugs. Annu. Rev. Pharmacol. Toxicol. 24:387-423
27. Rakotoarisoa L, Sayet I, Mironneau C, Mironneau J. 1990. Selective modulation by membrane potential of desmethoxyverapamil binding to calcium channels in rat portal vein. J. Pharmacol. Exp. Ther. 255:942-47
28. McDonald TF, Pelzer D, Trautwein W. 1984. Cat ventricular muscle treated with D600: characteristics of calcium channel block and unblock. J. Physiol. 352:217-41
29. McDonald TF, Pelzer D, Trautwein W. 1984. Cat ventricular muscle treated with D600: effects on calcium and potassium currents. J. Physiol. 352:203-16
30. Hering S, Bolton TB, Beech DJ, Lim SP. 1989. Mechanism of calcium channel block by D600 in single smooth muscle cells from rabbit ear artery. Circ. Res. 64:928-36
31. Herzig S, Lullmann H, Sieg H. 1992. Frequency- and potential-dependency of the negative inotropic action of various dihydropyridine and non-dihydropyridine calcium antagonists. Pharmacol. Toxicol. 71:229-35
32. Kanaya S, Arlock P, Katzung BG, Hondeghem LM. 1983. Diltiazem and verapamil preferentially block inactivated cardiac calcium channels. J. Mol. Cell. Cardiol. 15:145-48
33. Goll A, Glossmann H, Mannhold R. 1986. Correlation between the negative inotropic potency and binding parameters of 1,4-dihydropyridine and phenylalkylamine calcium channel blockers in cat heart. Arch. Pharmacol. 334:303-12
34. Johnson BJ, Hockerman GH, Scheuer T, Catterall WA. 1996. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Mol. Pharmacol. 50:1388-400
35. Hescheler J, Pelzer D, Trube G, Trautwein W. 1982. Does the organic calcium channel blocker D600 act from inside or outside on the cardiac cell membrane? Pflugers Arch. 393:287-91
36. Lee KS, Tsien RW. 1984. High selectivity of calcium channels in single dialysed heart cells of the guinea-pig. J. Physiol. 354:253-372
37. 2+ channel is accessible only from the extracellular side. Pflugers Arch. 424:552-54
38. Kass R, Arena JP, Chin S. 1991. Block of L-type calcium channels by charged dihydropyridines: sensitivity to side of application and calcium. J. Gen. Physiol. 98:63-75
39. 2+ channel in vascular smooth muscle cells: comparison with permanently charged derivative, D 890. Am. J. Physiol. 257:C689-95
40. Wegener JW, Nawrath H. 1995. Extracellular site of action of phenylalkylamines on L-type calcium current in rat ventricular myocytes. Naunyn-Schmiede. Arch. Pharmacol. 352:322-30
41. Striessnig J, Knaus HG, Grabner M, Moosburger K, Seitz W, et al. 1987. Photoaffinity labelling of the phenylalkylamine receptor of the skeletal muscle transverse-tubule calcium channel. FEBS Lett. 212:247-53
42. Curtis BM, Catterall WA. 1984. Purification of the calcium antagonist receptor of the voltage-sensitive calcium channel from skeletal muscle transverse tubules Biochemistry 23:2113-18
43. 2+ channels. Proc. Natl. Acad. Sci. USA 87:9108-12
44. Hockerman GH, Johnson BD, Scheuer T, Catterall WA. 1995. Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels. J. Biol. Chem. 270:22119-22
45. Schuster A, Lacinová L, Klugbauer N, Ito H, Birnbaumer L, Hofmann F. 1996. The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. EMBO J. 15:2365-70
46. 1A. J. Biol. Chem. 271:11745-49
47. 3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines. J. Pharmacol. Exp. Ther. 237:731-38
48. 2+ channel in cardiac tissue. Eur. J. Pharmacol. 280:155-58
49. Hockerman GH, Johnson BD, Abbott MR, Scheuer T, Catterall WA. 1997. Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane region IIIS6 and the pore region. Biophys. J. In press
50. Heinemann SH, Terlau H, Stühmer W, Imoto K, Numa S. 1992. Calcium channel characteristics conferred on the sodium channel by single mutations. Nature 356:441-43
51. 2+ channels. Nature 356:158-61
52. Tang S, Mikala G, Bahinski A, Yatani A, Varadi G, Schwartz A. 1993. Molecular localization of ion selectivity sites within the pore of a human L-type cardiac calcium channel. J. Biol. Chem. 268:13026-29
53. Suzuki T, Kurosawa H, Naito K, Otsuka M, Ohash M, Takaiti O. 1991. Binding characteristics of a new 1,5-benzothiazepine, clentiazem, to rat cerebral cortex and skeletal muscle membranes. Eur. J. Pharmacol. 194:195-200
54. 3H]TA-3090, a selective benzothiazepine-type calcium channel receptor antagonist: in vitro characterization. J. Pharmacol. Exp. Ther. 253:461-65
55. Kimball SD, Floyd DM, Das J, Hunt JT, Krapcho J, et al. 1992. Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site. J. Med. Chem. 35:780-93
56. 2+ channels. Mol. Pharmacol. 43:820-26
57. Nagao T, Sato M, Nakajima H, Kiyomoto A. 1973. Studies on a new 1,5-benzothiazepine derivative (CRD-401). IV. Coronary vasodilating effect and structure-activity relationship. Chem. Pharm. Bull. Tokyo 21:92-97
58. Floyd DM, Kimball SD, Krapcho J, Das J, Turk CF. 1992. Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones. J. Med. Chem. 35:756-72
59. Ferry DR, Glossmann H. 1982. Evidence of multiple receptor sites within the putative calcium channel. Naunyn-Schmiede. Arch. Pharmacol. 321:80-83
60. 3H]nitrendipine to membranes from coronary arteries and heart in relation to pharmacological effects. Paradoxical stimulation by diltiazem. Biochem. Biophys. Res. Commun. 108:110-17
61. 2+ channel inhibitors d-cis-diltiazem, (+/-)bepridil and (-)desmethoxyverapamil to their receptor site in skeletal muscle transverse tubule membranes. Biochem. Biophys. Res. Commun. 132: 49-55
62. 2+ channels in freshly dissociated rat cerebellar Purkinje neurons by diltiazem and verapamil. Brain Res. 695:88-91
63. Kimball SD, Hunt JT, Barrish JC, Das J, Floyd DM, et al. 1993. 1-Benzazepin-2-one calcium channel blockers - VI. Receptor-binding model and possible relationship to desmethoxyverapamil. Bioorg. Med. Chem. 1:285-307
64. Striessnig J, Scheffauer F, Mitterdorfer J, Schirmer M, Glossmann H. 1990. Identification of the benzothiazepine-binding polypeptide of skeletal muscle calcium channels with (+)-cis-azidodiltiazem and anti-ligand antibodies. J. Biol. Chem. 265:363-70
65. 3H]azidobutyryl diltiazem. J. Biol. Chem. 264:21211-14
66. Watanabe T, Kalasz H, Yabana H, Kuniyasu A, Mershon J, et al. 1993. Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the alpha 1 subunit of the skeletal muscle calcium channel. FEBS Lett. 334:261-64
67. Kraus R, Reichl B, Kimball SD, Grabner M, Murphy BJ, et al. 1996. Identification of benz(othi)azepine-binding regions within L-type channel α1 subunits. J. Biol. Chem. 271:20113-18
68. Hering S, Aczel S, Grabner M, Döring F, Berjukov S, et al. 1996. Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels. J. Biol. Chem. 271:24471-75
69. Bechem M, Schramm M. 1987. Calcium-agonists. J. Mol. Cell. Cardiol. 19:63-75
70. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. 1994. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol. Rev. 74:365-507
71. Williams JS, Grupp IL, Grupp G, Vaghy PL, Dumont L, et al. 1985. Profile of the oppositely acting enantiomers of the dihydropyridine 202-791 in cardiac preparations: receptor binding, electrophysiological, and pharmacological studies. Biochem. Biophys. Res. Commun. 131:13-21
72. Kamp TJ, Sanguinetti MC, Miller RJ. 1989. Voltage- and use-dependent modulation of cardiac calcium channels by the dihydropyridine (+)-202-791. Circ. Res. 64:338-51
73. Kass RS. 1987. Voltage-dependent modulation of cardiac calcium channel current by optical isomers of Bay K 8644: implications for channel gating. Circ. Res. 61:11-15
74. Kokubun S, Prod'hom B, Becker C, Porzig H, Reuter H. 1986. Studies on Ca channels in intact cardiac cells: voltage-dependent effects and cooperative interactions of dihydropyridine enantiomers. Mol. Pharmacol. 30:571-84
75. Bean BP. 1984. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc. Natl. Acad. Sci. USA 81:6388-92
76. Kokubun S, Reuter H. 1984. Dihydropyridine derivatives prolong the open state of Ca channels in cultured cardiac cells. Proc. Natl. Acad. Sci. USA 81:4824-27
77. Hamilton SL, Yatani A, Brush K, Schwartz A, Brown AM. 1987. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes. Mol. Pharmacol. 31:221-31
78. 2+ channel splice variants. J. Biol. Chem. 270:10540-43
79. Gurney AM, Nerbonne JM, Lester HA. 1985. Photoinduced removal of nifedipine reveals mechanisms of calcium antagonist action on single heart cells. J. Gen. Physiol. 86:353-79
80. Cohen CJ, McCarthy RT. 1987. Nimodipine block of calcium channels in rat anterior pituitary cells. J. Physiol. 387:195-225
81. Hess P, Lansman JB, Tsien RW. 1984. Differential modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature 311:538-44
82. Sanguinetti MC, Krafte DS, Kass RS. 1986. Voltage-dependent modulation of Ca channel current in heart cells by Bay K8644. J. Gen. Physiol. 88:369-92
83. Lacerda AE, Brown AM. 1989. Non-modal gating of cardiac calcium channels as revealed by dihydropyridines. J. Gen. Physiol. 93:1243-73
84. Marks TN, Jones SW. 1992. An allosteric model for calcium channel activation and dihydropyridine agonist action. J. Gen. Physiol. 99:367-90
85. o on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor. J. Gen. Physiol. 93:1109-27
86. Strübing C, Hering S, Glossmann H. 1993. Evidence for an external location of the dihydropyridine agonist receptor site on smooth muscle and skeletal muscle calcium channels. Br. J. Pharmacol. 108:884-91
87. Herbette LG, Vant-Erve VM, Rhodes DG. 1989. Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors. J. Mol. Cell. Cardiol. 21:187-201
88. Bangalore R, Baindur N, Rutledge A, Triggle DJ, Kass RS. 1994. L-type calcium channels: Asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines. Mol. Pharmacol. 46:660-66
89. 3H]azidopine. FEBS Lett. 169:112-67
90. 2+ channel inhibitors d-cis-diltiazem, (+)-bepridil, desmethoxyverapamil and (+)PN200-100 in skeletal muscle transverse tubule membranes. J. Biol. Chem. 261:1393-97
91. Sharp AH, Imagawa T, Leung AT, Campbell KP. 1987. Identification and characterization of the dihydropyridine-binding subunit of the skeletal muscle dihydropyridine receptor. J. Biol. Chem. 262:12309-15
92. Takahashi M, Seagar MJ, Jones JF, Reber BF, Catterall WA. 1987. Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. Proc. Natl. Acad. Sci. USA 84:5478-82
93. Vaghy PL, Striessnig J, Miwa K, Knaus H-G, Itagaki K, et al. 1987. Identification of a novel 1,4-dihydropyridine- and phenylalkylamine-binding polypeptide in calcium channel preparations. J. Biol. Chem. 262:14337-42
94. Sieber M, Nastainczyk W, Zubor V, Wernet W, Hofmann F. 1987. The 165-kDa peptide of the purified skeletal muscle dihydropyridine receptor contains the known regulatory sites of the calcium channel. Eur. J. Biochem. 167:117-22
95. Hosey MM, Barhanin J, Schmid A, Vandaele S, Ptasienski J, et al. 1987. Photoaffinity labelling and phosphorylation of a 165 kilodalton peptide associated with dihydropyridine and phenylalkylamine-sensitive calcium channels. Biochem. Biophys. Res. Commun. 147:1137-45
96. 1 subunit. EMBO J. 10:45-49
97. 2+ channels by photoaffinity labeling with diazipine. Proc. Natl. Acad. Sci. USA 88:9203-7
98. 1 subunit. Proc. Natl. Acad. Sci. USA 88:10769-73
99. Kalasz H, Watanabe T, Yabana H, Itagaki K, Naito K, et al. 1993. Identification of 1,4-dihydropyridine binding domains within the primary structure of the alpha 1 subunit of the skeletal muscle L-type calcium channel. FEBS Lett. 331:177-81
100. Tang S, Yatani A, Bahinski A, Mori Y, Schwartz A. 1993. Molecular localization of regions in the L-type calcium channel critical for dihydropyridine action. Neuron 11:1013-21
101. Grabner M, Wang ZY, Hering S, Striessnig J, Glossmann H. 1996. Transfer of 1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels. Neuron 16:207-18
102. 2/δ subunits in a somatic cell line. J. Physiol. 471:749-65
103. Peterson BZ, Tanada TN, Catterall WA. 1996. Molecular determinants of high affinity dihydropyridine binding in L-type calcium channels. J. Biol. Chem. 271:5293-96
104. Peterson BZ, Hockerman GH, Abbot MR, Johnson BD, Scheuer T, Catterall WA. 1996. Analysis of the dihydropyridine receptor site of L-type calcium channels by alanine-scanning mutagenesis of transmembrane segments IIIS6 and IVS6. Biophys. J. In press
105. Blaber M, Zhang XJ, Matthews BW. 1993. Structural basis of amino acid alpha helix propensity. Science 260:1637-40
106. 2+ channel antagonists. Trends Pharmacol. Sci. 13:256-62
107. Glossmann H, Ferry DR, Goll A, Striessnig J, Zernig G. 1985. Calcium channels and calcium channel drugs: recent biochemical and biophysical findings. Arzneimittelforschung 35:1917-35
108. Peterson BZ, Catterall WA. 1995. Calcium binding in the pore of L-type calcium channels modulates high affinity dihydropyridine binding. J. Biol. Chem. 270:18201-4
109. 1 subunit. Biochemistry 34:9350-55
110. Hess P, Tsien RW. 1984. Mechanism of ion permeation through calcium channels. Nature 309:453-56
111. ++. J. Physiol. 353:565-83
112. Sather WA, Yang J, Tsien RW. 1994. Structural basis of ion channel permeation and selectivity. Curr. Opin. Neurobiol. 4:313-23
113. 3H]Bay k 8644, to membranes from cardiac muscle and brain. Biochem. Biophys. Res. Commun. 121:317-23
114. Brown AM, Kunze DL, Yatani A. 1986. Dual effects of dihydropyridines on whole cell and unitary calcium currents in single ventricular cells of guinea-pig. J. Physiol. 379:495-514
115. + channels by local anesthetics. Science 265:1724-28
116. Zhang Y, Liang J-Y, Huang S, Lipscomb WN. 1994. Toward a mechanism for the allosteric transition of pig kidney fructose-1,6-bisphosphatase. J. Mol. Biol. 244:609-24
117. Kantrowitz ER, Lipscomb WN. 1990. Escherichia coli aspartate transcarbamoylase: the molecular basis for a concerted allosteric transition. Trends Biochem. Sci. 15:53-59
118. Barford D, Johnson LN. 1989. The allosteric transition of glycogen phosphorylase. Nature 340:609-16
119. Karlin A, Akabas MH. 1995. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15:1231-44
120. Deleted in proof
121. Starr TVB, Prystay W, Snutch TP. 1992. Primary structure of a calcium channel that is highly expressed in rat cerebellum Proc. Natl. Acad. Sci. USA 88:5621-25
122. Dubel SJ, Starr TVB, Hell J, Ahlijanian MK, Enyeart JJ, et al. 1992. Molecular cloning of the α-1 subunit of an ω-conotoxin-sensitive calcium channel. Proc. Natl. Acad. Sci. USA 89:5058-62
123. 1 subunit of the voltage-dependent calcium channel. Neuron 7:35-44
124. Mori Y, Friedrich T, Kim M-S, Mikami A, Nakai J, et al. 1991. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature 350:398-402
125. Friedrich T, Mori Y. 1992. Molecular cloning and characterization of a novel calcium channel from rabbit brain. FEBS Lett. 308:7-13